FibroGen Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
486
- Stock Symbol
-
FGEN
- Share Price
-
$0.50
- (As of Friday Closing)
FibroGen General Information
Description
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Contact Information
Website
www.fibrogen.comCorporate Office
- 350 Bay Street
- Suite 100 Number 6009
- San Francisco, CA 94133
- United States
Corporate Office
- 350 Bay Street
- Suite 100 Number 6009
- San Francisco, CA 94133
- United States
FibroGen Stock Performance
As of 07-Feb-2025, FibroGen’s stock price is $0.50. Its current market cap is $50.7M with 101M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.50 | $0.50 | $0.18 - $2.93 | $50.7M | 101M | 1.29M | -$1.23 |
FibroGen Financials Summary
As of 30-Sep-2024, FibroGen has a trailing 12-month revenue of $180M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 87,738 | 91,471 | 1,209,244 | 942,408 |
| Revenue | 180,015 | 147,752 | 140,734 | 235,309 |
| EBITDA | (108,740) | (271,885) | (290,421) | (273,721) |
| Net Income | (121,793) | (284,232) | (293,654) | (290,023) |
| Total Assets | 264,421 | 423,529 | 610,087 | 773,821 |
| Total Debt | 79,337 | 152,548 | 89,885 | 99,720 |
FibroGen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
FibroGen Comparisons
Industry
Financing
Details
FibroGen Competitors (39)
One of FibroGen’s 39 competitors is Pliant Therapeutics, a Formerly VC-backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pliant Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| BenevolentAI | Formerly PE-Backed | London, United Kingdom | ||||
| Santhera Pharmaceuticals | Private Debt Financed | Pratteln, Switzerland | ||||
| Organogenesis Holdings | Pending Transaction (M&A) | Canton, MA | ||||
| Adverum Biotechnologies | Formerly VC-backed | Redwood City, CA |
FibroGen Patents
FibroGen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023308640-A1 | Modified anti-galectin-9 antibody and uses thereof | Pending | 15-Jul-2022 | ||
| AU-2023207157-A1 | Treatment for congestive heart failure | Pending | 13-Jan-2022 | ||
| EP-4463160-A1 | Treatment for congestive heart failure | Pending | 13-Jan-2022 | ||
| AU-2021331480-A1 | Compounds, compositions and methods for histone lysine demethylase inhibition | Pending | 28-Aug-2020 | ||
| EP-4204400-A1 | Compounds, compositions and methods for histone lysine demethylase inhibition | Inactive | 28-Aug-2020 | C07D213/84 |
FibroGen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
FibroGen ESG
Risk Overview
Risk Rating
Updated October, 17, 2024
27.73 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile
Pharmaceuticals
Industry
of 853
Rank
Percentile
Biotechnology
Subindustry
of 368
Rank
Percentile
FibroGen FAQs
-
When was FibroGen founded?
FibroGen was founded in 1993.
-
Where is FibroGen headquartered?
FibroGen is headquartered in San Francisco, CA.
-
What is the size of FibroGen?
FibroGen has 486 total employees.
-
What industry is FibroGen in?
FibroGen’s primary industry is Drug Discovery.
-
Is FibroGen a private or public company?
FibroGen is a Public company.
-
What is FibroGen’s stock symbol?
The ticker symbol for FibroGen is FGEN.
-
What is the current stock price of FibroGen?
As of 07-Feb-2025 the stock price of FibroGen is $0.50.
-
What is the current market cap of FibroGen?
The current market capitalization of FibroGen is $50.7M.
-
What is FibroGen’s current revenue?
The trailing twelve month revenue for FibroGen is $180M.
-
Who are FibroGen’s competitors?
Pliant Therapeutics, BenevolentAI, Santhera Pharmaceuticals, Organogenesis Holdings, and Adverum Biotechnologies are some of the 39 competitors of FibroGen.
-
What is FibroGen’s annual earnings per share (EPS)?
FibroGen’s EPS for 12 months was -$1.23.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
